(Reuters) – Novartis AG on Wednesday got U.S. approval for its drug Tabrecta, to treat patients with a form of lung cancer, according to the U.S. Food and Drug Administration’s website.
The drug has been approved to treat non-small cell lung cancer that has spread to other parts of the body, the FDA said. (https://bit.ly/2YGybmg)
The drug got a priority review from the FDA in February.
(Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta)
